Ref.: BL-RE-092268Manufacturer ref.: EHTNFRSF10BX10 10 x 96 tests
€4,815.00 excl. VAT
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified receptor containing a TRAIL-induced death domain of TRAIL-induced apoptosis. DR5 is a member of the TNF receptor superfamily and contains a field of death...
Accession number
O14763
Dose range
2.46 to 600 pg/ml
Sensitivity of the dosage
2 pg/ml
Conjugate
Biotin
Product type
ELISA
Brand
Invitrogen
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified receptor containing a TRAIL-induced death domain of TRAIL-induced apoptosis. DR5 is a member of the TNF receptor superfamily and contains a field of death...
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified receptor containing a TRAIL death domain that regulates TRAIL-induced apoptosis. DR5 is a member of the TNF receptor superfamily and contains an intracellular death domain. DR5 can be activated by the tumour necrosis factor (TNFSF10 / TRAIL / APO-2L)-induced inducer ligand apoptosis signal. Studies in FADD-deficient mice suggest that FADD, an adaptive protein containing a field of death, is required for DR5-induced apoptosis. Two different isoform transcription variants of DR5 and a non-coding transcription were identified. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in many cell types, at particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include epidermoid carcinoma and diffuse infiltrating lymphocyte syndrome.
Sensitivity
Sensitivity of dosage: 2 pg/ml.
Measurement range
Dosing range: 2.46 to 600 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.